Enterococcus faecalis
Antibiotic |
% Susceptible 2010 |
% Susceptible 2012 |
% Susceptible 2014 |
% Susceptible 2016 |
% Susceptible 2018 |
Ampicillin | 100 |
100 | 100 | 100 | 99 |
Azithromycin | - |
- | - |
- | - |
Aztreonam | - |
- | - |
- | - |
Cefazolin | - |
- | -
- |
- |
|
Cefepime | - |
- | -
- |
- |
|
Ceftazidime | - |
- | - |
- | - |
Ceftriaxone | - |
- | - |
- | - |
Cefuroxime | - |
- | -
- |
- |
|
Ciprofloxacin | 61 |
72 | 69 |
77 | 75 |
Clarithromycin | - |
- | - |
- | - |
Clindamycin | - |
- | - |
- | - |
Doxycycline | 20 |
20 | 23 |
24 | 24 |
Erythromycin | - |
- | - |
- | 24 |
Gentamicin | 71S |
75S | 75S |
79S | 79S |
Imipenem | + |
+ | + |
+ | + |
Levofloxacin | 67 | 78 | 74 | 81 | 85 |
Meropenem | +/- | +/- | +/- | +/- | +/- |
Moxifloxacin | + | + | + | + | + |
Nitrofurantoin | 99& | 99& | 99& | 99& | 99& |
Oxacillin/Naf | - | - | - | - | - |
Penicillin | 100 | 100 | 100 | 100 | 99 |
Piperacillin | + | + | + | + | + |
Piperacillin/tazo | + | + | + | + | + |
Ticarcillin/Clav | +/- | +/- | +/- | +/- | +/- |
Tobramycin | S | S | S | S | S |
TMP/SMX | - | - | - | - | - |
Unasyn/Aug | + | + | + | + | + |
Vancomycin | 100 | 100 | 100 | 99 | 99 |
# Tested | 758 | 752 | 770 | 742 | 832 |
Comments:
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections